Core Viewpoint - Quantum BioPharma Ltd. held its annual general and special meeting of shareholders on September 26, 2025, where significant corporate governance decisions were made, including the election of directors and the re-appointment of auditors [1][2][3]. Shareholder Representation - At the AGSM, shareholders represented 100% of Class A Multiple Voting Shares and 46.352% of Class B Subordinate Voting Shares, with Class A shares providing 276,660 votes each [2]. Election of Directors - All nominees listed in the management information circular dated August 14, 2025, were elected as directors, with votes for each nominee exceeding 99% [3]. Auditor Re-appointment - MNP LLP was re-appointed as the Company's auditor with 99.588% of votes in favor, and the directors were authorized to fix the auditor's remuneration [4]. Class A Multiple Voting Shares Issuance - An ordinary resolution was passed allowing the Board to approve the issuance of up to 56 additional Class A Multiple Voting Shares until the next annual meeting, with 90.992% of votes in favor [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various development stages [5][6]. Lead Compound Development - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation associated with multiple sclerosis, showing promise in preclinical models [6]. Strategic Investments - Quantum BioPharma maintains a strategic investment portfolio through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial properties [6].
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders